Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
Title:
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
Author:
Souglakos, J. Boukovinas, I. Kakolyris, S. Xynogalos, S. Ziras, N. Athanasiadis, A. Androulakis, N. Christopoulou, A. Vaslamatzis, M. Ardavanis, A. Emmanouilides, C. Bompolaki, I. Kourousis, C. Makrantonakis, P. Christofyllakis, C. Athanasiadis, E. Kentepozidis, N. Karampeazis, A. Katopodi, U. Anagnosopoulos, A. Papadopoulos, G. Prinarakis, E. Kalisperi, A. Mavroudis, D. Georgoulias, V.